nodes	percent_of_prediction	percent_of_DWPC	metapath
Duloxetine—HTR2A—trigeminal nucleus—multiple sclerosis	0.049	0.214	CbGeAlD
Duloxetine—NPY1R—nerve—multiple sclerosis	0.023	0.1	CbGeAlD
Duloxetine—HTR2A—trigeminal nerve—multiple sclerosis	0.0129	0.0561	CbGeAlD
Duloxetine—SLC6A3—nerve—multiple sclerosis	0.00969	0.0422	CbGeAlD
Duloxetine—HTR2A—pons—multiple sclerosis	0.00906	0.0395	CbGeAlD
Duloxetine—SLC6A2—nerve—multiple sclerosis	0.00782	0.0341	CbGeAlD
Duloxetine—HTR2A—pineal body—multiple sclerosis	0.00647	0.0282	CbGeAlD
Duloxetine—HTR2A—peripheral nervous system—multiple sclerosis	0.00603	0.0263	CbGeAlD
Duloxetine—NPY1R—nervous system—multiple sclerosis	0.00518	0.0226	CbGeAlD
Duloxetine—NPY1R—central nervous system—multiple sclerosis	0.00499	0.0217	CbGeAlD
Duloxetine—HTR2A—nerve—multiple sclerosis	0.0047	0.0205	CbGeAlD
Duloxetine—SLC6A3—brainstem—multiple sclerosis	0.00416	0.0181	CbGeAlD
Duloxetine—HTR2C—brainstem—multiple sclerosis	0.00402	0.0175	CbGeAlD
Duloxetine—NPY1R—brain—multiple sclerosis	0.00396	0.0173	CbGeAlD
Duloxetine—SLC6A4—brainstem—multiple sclerosis	0.00381	0.0166	CbGeAlD
Duloxetine—HTR6—nervous system—multiple sclerosis	0.00364	0.0159	CbGeAlD
Duloxetine—HTR6—central nervous system—multiple sclerosis	0.00351	0.0153	CbGeAlD
Duloxetine—SLC6A2—brainstem—multiple sclerosis	0.00335	0.0146	CbGeAlD
Duloxetine—HTR2C—medulla oblongata—multiple sclerosis	0.0028	0.0122	CbGeAlD
Duloxetine—HTR6—brain—multiple sclerosis	0.00279	0.0121	CbGeAlD
Duloxetine—SLC6A3—midbrain—multiple sclerosis	0.00265	0.0116	CbGeAlD
Duloxetine—SLC6A3—spinal cord—multiple sclerosis	0.00259	0.0113	CbGeAlD
Duloxetine—HTR2C—midbrain—multiple sclerosis	0.00256	0.0112	CbGeAlD
Duloxetine—HTR2C—spinal cord—multiple sclerosis	0.0025	0.0109	CbGeAlD
Duloxetine—SLC6A4—midbrain—multiple sclerosis	0.00243	0.0106	CbGeAlD
Duloxetine—SLC6A4—spinal cord—multiple sclerosis	0.00237	0.0103	CbGeAlD
Duloxetine—SLC6A2—medulla oblongata—multiple sclerosis	0.00234	0.0102	CbGeAlD
Duloxetine—SLC6A3—nervous system—multiple sclerosis	0.00218	0.0095	CbGeAlD
Duloxetine—HTR2C—nervous system—multiple sclerosis	0.00211	0.00918	CbGeAlD
Duloxetine—SLC6A3—central nervous system—multiple sclerosis	0.0021	0.00914	CbGeAlD
Duloxetine—SLC6A3—cerebellum—multiple sclerosis	0.00205	0.00894	CbGeAlD
Duloxetine—HTR2C—central nervous system—multiple sclerosis	0.00203	0.00884	CbGeAlD
Duloxetine—HTR2A—brainstem—multiple sclerosis	0.00202	0.00879	CbGeAlD
Duloxetine—SLC6A4—nervous system—multiple sclerosis	0.002	0.0087	CbGeAlD
Duloxetine—HTR2A—retina—multiple sclerosis	0.00195	0.00848	CbGeAlD
Duloxetine—SLC6A4—central nervous system—multiple sclerosis	0.00192	0.00838	CbGeAlD
Duloxetine—CYP2D6—brainstem—multiple sclerosis	0.00184	0.00801	CbGeAlD
Duloxetine—SLC6A2—nervous system—multiple sclerosis	0.00176	0.00766	CbGeAlD
Duloxetine—SLC6A2—central nervous system—multiple sclerosis	0.00169	0.00738	CbGeAlD
Duloxetine—SLC6A3—brain—multiple sclerosis	0.00167	0.00726	CbGeAlD
Duloxetine—HTR2C—brain—multiple sclerosis	0.00161	0.00702	CbGeAlD
Duloxetine—SLC6A4—brain—multiple sclerosis	0.00153	0.00665	CbGeAlD
Duloxetine—HTR2A—medulla oblongata—multiple sclerosis	0.00141	0.00613	CbGeAlD
Duloxetine—SLC6A2—brain—multiple sclerosis	0.00134	0.00586	CbGeAlD
Duloxetine—HTR2A—midbrain—multiple sclerosis	0.00129	0.0056	CbGeAlD
Duloxetine—HTR2A—spinal cord—multiple sclerosis	0.00125	0.00547	CbGeAlD
Duloxetine—HTR2A—nervous system—multiple sclerosis	0.00106	0.00461	CbGeAlD
Duloxetine—HTR2A—central nervous system—multiple sclerosis	0.00102	0.00443	CbGeAlD
Duloxetine—HTR2A—cerebellum—multiple sclerosis	0.000994	0.00433	CbGeAlD
Duloxetine—CYP2D6—nervous system—multiple sclerosis	0.000962	0.0042	CbGeAlD
Duloxetine—CYP2D6—central nervous system—multiple sclerosis	0.000927	0.00404	CbGeAlD
Duloxetine—CYP2D6—cerebellum—multiple sclerosis	0.000906	0.00395	CbGeAlD
Duloxetine—HTR2A—brain—multiple sclerosis	0.000808	0.00352	CbGeAlD
Duloxetine—CYP2D6—brain—multiple sclerosis	0.000736	0.00321	CbGeAlD
Duloxetine—Epistaxis—Methotrexate—multiple sclerosis	0.000353	0.000624	CcSEcCtD
Duloxetine—Hypersensitivity—Mitoxantrone—multiple sclerosis	0.000353	0.000624	CcSEcCtD
Duloxetine—Paraesthesia—Prednisolone—multiple sclerosis	0.000353	0.000624	CcSEcCtD
Duloxetine—Tachycardia—Triamcinolone—multiple sclerosis	0.000353	0.000623	CcSEcCtD
Duloxetine—Mental disorder—Prednisone—multiple sclerosis	0.000352	0.000622	CcSEcCtD
Duloxetine—Nausea—Azathioprine—multiple sclerosis	0.000352	0.000622	CcSEcCtD
Duloxetine—Tachycardia—Methylprednisolone—multiple sclerosis	0.000352	0.000622	CcSEcCtD
Duloxetine—Skin disorder—Methylprednisolone—multiple sclerosis	0.00035	0.000619	CcSEcCtD
Duloxetine—Erythema—Prednisone—multiple sclerosis	0.00035	0.000618	CcSEcCtD
Duloxetine—Malnutrition—Prednisone—multiple sclerosis	0.00035	0.000618	CcSEcCtD
Duloxetine—Hyperhidrosis—Triamcinolone—multiple sclerosis	0.000349	0.000617	CcSEcCtD
Duloxetine—Hyperhidrosis—Methylprednisolone—multiple sclerosis	0.000349	0.000616	CcSEcCtD
Duloxetine—Convulsion—Betamethasone—multiple sclerosis	0.000348	0.000615	CcSEcCtD
Duloxetine—Convulsion—Dexamethasone—multiple sclerosis	0.000348	0.000615	CcSEcCtD
Duloxetine—Hypertension—Betamethasone—multiple sclerosis	0.000347	0.000613	CcSEcCtD
Duloxetine—Hypertension—Dexamethasone—multiple sclerosis	0.000347	0.000613	CcSEcCtD
Duloxetine—Asthenia—Mitoxantrone—multiple sclerosis	0.000344	0.000607	CcSEcCtD
Duloxetine—Myalgia—Dexamethasone—multiple sclerosis	0.000342	0.000605	CcSEcCtD
Duloxetine—Myalgia—Betamethasone—multiple sclerosis	0.000342	0.000605	CcSEcCtD
Duloxetine—Anxiety—Betamethasone—multiple sclerosis	0.000341	0.000602	CcSEcCtD
Duloxetine—Anxiety—Dexamethasone—multiple sclerosis	0.000341	0.000602	CcSEcCtD
Duloxetine—Discomfort—Dexamethasone—multiple sclerosis	0.000338	0.000597	CcSEcCtD
Duloxetine—Discomfort—Betamethasone—multiple sclerosis	0.000338	0.000597	CcSEcCtD
Duloxetine—Haemoglobin—Methotrexate—multiple sclerosis	0.000338	0.000597	CcSEcCtD
Duloxetine—Pain—Prednisolone—multiple sclerosis	0.000336	0.000594	CcSEcCtD
Duloxetine—Hepatitis—Methotrexate—multiple sclerosis	0.000336	0.000594	CcSEcCtD
Duloxetine—Haemorrhage—Methotrexate—multiple sclerosis	0.000336	0.000594	CcSEcCtD
Duloxetine—Pharyngitis—Methotrexate—multiple sclerosis	0.000333	0.000589	CcSEcCtD
Duloxetine—Urinary tract disorder—Methotrexate—multiple sclerosis	0.000332	0.000586	CcSEcCtD
Duloxetine—Vision blurred—Prednisone—multiple sclerosis	0.00033	0.000583	CcSEcCtD
Duloxetine—Urethral disorder—Methotrexate—multiple sclerosis	0.000329	0.000582	CcSEcCtD
Duloxetine—Musculoskeletal discomfort—Triamcinolone—multiple sclerosis	0.000329	0.000582	CcSEcCtD
Duloxetine—Musculoskeletal discomfort—Methylprednisolone—multiple sclerosis	0.000328	0.000581	CcSEcCtD
Duloxetine—Anaphylactic shock—Dexamethasone—multiple sclerosis	0.000328	0.00058	CcSEcCtD
Duloxetine—Anaphylactic shock—Betamethasone—multiple sclerosis	0.000328	0.00058	CcSEcCtD
Duloxetine—Oedema—Betamethasone—multiple sclerosis	0.000328	0.00058	CcSEcCtD
Duloxetine—Oedema—Dexamethasone—multiple sclerosis	0.000328	0.00058	CcSEcCtD
Duloxetine—Diarrhoea—Mitoxantrone—multiple sclerosis	0.000328	0.000579	CcSEcCtD
Duloxetine—Insomnia—Triamcinolone—multiple sclerosis	0.000327	0.000578	CcSEcCtD
Duloxetine—Insomnia—Methylprednisolone—multiple sclerosis	0.000326	0.000576	CcSEcCtD
Duloxetine—Infection—Betamethasone—multiple sclerosis	0.000326	0.000576	CcSEcCtD
Duloxetine—Infection—Dexamethasone—multiple sclerosis	0.000326	0.000576	CcSEcCtD
Duloxetine—Ill-defined disorder—Prednisone—multiple sclerosis	0.000325	0.000574	CcSEcCtD
Duloxetine—Paraesthesia—Triamcinolone—multiple sclerosis	0.000324	0.000574	CcSEcCtD
Duloxetine—Feeling abnormal—Prednisolone—multiple sclerosis	0.000324	0.000572	CcSEcCtD
Duloxetine—Paraesthesia—Methylprednisolone—multiple sclerosis	0.000324	0.000572	CcSEcCtD
Duloxetine—Visual impairment—Methotrexate—multiple sclerosis	0.000324	0.000572	CcSEcCtD
Duloxetine—Anaemia—Prednisone—multiple sclerosis	0.000323	0.000572	CcSEcCtD
Duloxetine—Shock—Betamethasone—multiple sclerosis	0.000323	0.00057	CcSEcCtD
Duloxetine—Shock—Dexamethasone—multiple sclerosis	0.000323	0.00057	CcSEcCtD
Duloxetine—Nervous system disorder—Betamethasone—multiple sclerosis	0.000321	0.000568	CcSEcCtD
Duloxetine—Nervous system disorder—Dexamethasone—multiple sclerosis	0.000321	0.000568	CcSEcCtD
Duloxetine—Agitation—Prednisone—multiple sclerosis	0.000321	0.000568	CcSEcCtD
Duloxetine—Thrombocytopenia—Betamethasone—multiple sclerosis	0.000321	0.000567	CcSEcCtD
Duloxetine—Thrombocytopenia—Dexamethasone—multiple sclerosis	0.000321	0.000567	CcSEcCtD
Duloxetine—Tachycardia—Betamethasone—multiple sclerosis	0.00032	0.000566	CcSEcCtD
Duloxetine—Tachycardia—Dexamethasone—multiple sclerosis	0.00032	0.000566	CcSEcCtD
Duloxetine—Angioedema—Prednisone—multiple sclerosis	0.00032	0.000565	CcSEcCtD
Duloxetine—Dyspepsia—Triamcinolone—multiple sclerosis	0.000318	0.000562	CcSEcCtD
Duloxetine—Erythema multiforme—Methotrexate—multiple sclerosis	0.000318	0.000561	CcSEcCtD
Duloxetine—Dyspepsia—Methylprednisolone—multiple sclerosis	0.000317	0.000561	CcSEcCtD
Duloxetine—Hyperhidrosis—Betamethasone—multiple sclerosis	0.000317	0.00056	CcSEcCtD
Duloxetine—Hyperhidrosis—Dexamethasone—multiple sclerosis	0.000317	0.00056	CcSEcCtD
Duloxetine—Malaise—Prednisone—multiple sclerosis	0.000315	0.000558	CcSEcCtD
Duloxetine—Vertigo—Prednisone—multiple sclerosis	0.000314	0.000556	CcSEcCtD
Duloxetine—Eye disorder—Methotrexate—multiple sclerosis	0.000314	0.000555	CcSEcCtD
Duloxetine—Syncope—Prednisone—multiple sclerosis	0.000314	0.000555	CcSEcCtD
Duloxetine—Tinnitus—Methotrexate—multiple sclerosis	0.000313	0.000554	CcSEcCtD
Duloxetine—Anorexia—Betamethasone—multiple sclerosis	0.000312	0.000552	CcSEcCtD
Duloxetine—Anorexia—Dexamethasone—multiple sclerosis	0.000312	0.000552	CcSEcCtD
Duloxetine—Urticaria—Prednisolone—multiple sclerosis	0.000312	0.000552	CcSEcCtD
Duloxetine—Cardiac disorder—Methotrexate—multiple sclerosis	0.000312	0.000551	CcSEcCtD
Duloxetine—Fatigue—Triamcinolone—multiple sclerosis	0.000311	0.000551	CcSEcCtD
Duloxetine—Fatigue—Methylprednisolone—multiple sclerosis	0.000311	0.000549	CcSEcCtD
Duloxetine—Pain—Triamcinolone—multiple sclerosis	0.000309	0.000546	CcSEcCtD
Duloxetine—Loss of consciousness—Prednisone—multiple sclerosis	0.000307	0.000544	CcSEcCtD
Duloxetine—Angiopathy—Methotrexate—multiple sclerosis	0.000305	0.000539	CcSEcCtD
Duloxetine—Vomiting—Mitoxantrone—multiple sclerosis	0.000304	0.000538	CcSEcCtD
Duloxetine—Immune system disorder—Methotrexate—multiple sclerosis	0.000303	0.000536	CcSEcCtD
Duloxetine—Convulsion—Prednisone—multiple sclerosis	0.000303	0.000536	CcSEcCtD
Duloxetine—Mediastinal disorder—Methotrexate—multiple sclerosis	0.000303	0.000535	CcSEcCtD
Duloxetine—Hypertension—Prednisone—multiple sclerosis	0.000302	0.000534	CcSEcCtD
Duloxetine—Rash—Mitoxantrone—multiple sclerosis	0.000302	0.000534	CcSEcCtD
Duloxetine—Dermatitis—Mitoxantrone—multiple sclerosis	0.000302	0.000533	CcSEcCtD
Duloxetine—Chills—Methotrexate—multiple sclerosis	0.000301	0.000533	CcSEcCtD
Duloxetine—Headache—Mitoxantrone—multiple sclerosis	0.0003	0.00053	CcSEcCtD
Duloxetine—Musculoskeletal discomfort—Betamethasone—multiple sclerosis	0.000299	0.000528	CcSEcCtD
Duloxetine—Musculoskeletal discomfort—Dexamethasone—multiple sclerosis	0.000299	0.000528	CcSEcCtD
Duloxetine—Arthralgia—Prednisone—multiple sclerosis	0.000298	0.000526	CcSEcCtD
Duloxetine—Myalgia—Prednisone—multiple sclerosis	0.000298	0.000526	CcSEcCtD
Duloxetine—Feeling abnormal—Triamcinolone—multiple sclerosis	0.000298	0.000526	CcSEcCtD
Duloxetine—Feeling abnormal—Methylprednisolone—multiple sclerosis	0.000297	0.000525	CcSEcCtD
Duloxetine—Anxiety—Prednisone—multiple sclerosis	0.000297	0.000525	CcSEcCtD
Duloxetine—Alopecia—Methotrexate—multiple sclerosis	0.000297	0.000525	CcSEcCtD
Duloxetine—Insomnia—Dexamethasone—multiple sclerosis	0.000297	0.000524	CcSEcCtD
Duloxetine—Insomnia—Betamethasone—multiple sclerosis	0.000297	0.000524	CcSEcCtD
Duloxetine—Unspecified disorder of skin and subcutaneous tissue—Prednisone—multiple sclerosis	0.000296	0.000523	CcSEcCtD
Duloxetine—Gastrointestinal pain—Methylprednisolone—multiple sclerosis	0.000295	0.000521	CcSEcCtD
Duloxetine—Paraesthesia—Betamethasone—multiple sclerosis	0.000294	0.00052	CcSEcCtD
Duloxetine—Paraesthesia—Dexamethasone—multiple sclerosis	0.000294	0.00052	CcSEcCtD
Duloxetine—Discomfort—Prednisone—multiple sclerosis	0.000294	0.00052	CcSEcCtD
Duloxetine—Mental disorder—Methotrexate—multiple sclerosis	0.000294	0.00052	CcSEcCtD
Duloxetine—Erythema—Methotrexate—multiple sclerosis	0.000292	0.000517	CcSEcCtD
Duloxetine—Malnutrition—Methotrexate—multiple sclerosis	0.000292	0.000517	CcSEcCtD
Duloxetine—Hypersensitivity—Prednisolone—multiple sclerosis	0.000289	0.000512	CcSEcCtD
Duloxetine—Dyspepsia—Betamethasone—multiple sclerosis	0.000289	0.00051	CcSEcCtD
Duloxetine—Dyspepsia—Dexamethasone—multiple sclerosis	0.000289	0.00051	CcSEcCtD
Duloxetine—Urticaria—Triamcinolone—multiple sclerosis	0.000287	0.000507	CcSEcCtD
Duloxetine—Urticaria—Methylprednisolone—multiple sclerosis	0.000286	0.000506	CcSEcCtD
Duloxetine—Dysgeusia—Methotrexate—multiple sclerosis	0.000286	0.000506	CcSEcCtD
Duloxetine—Body temperature increased—Triamcinolone—multiple sclerosis	0.000286	0.000505	CcSEcCtD
Duloxetine—Oedema—Prednisone—multiple sclerosis	0.000285	0.000505	CcSEcCtD
Duloxetine—Anaphylactic shock—Prednisone—multiple sclerosis	0.000285	0.000505	CcSEcCtD
Duloxetine—Abdominal pain—Methylprednisolone—multiple sclerosis	0.000285	0.000504	CcSEcCtD
Duloxetine—Decreased appetite—Betamethasone—multiple sclerosis	0.000285	0.000504	CcSEcCtD
Duloxetine—Decreased appetite—Dexamethasone—multiple sclerosis	0.000285	0.000504	CcSEcCtD
Duloxetine—Nausea—Mitoxantrone—multiple sclerosis	0.000284	0.000503	CcSEcCtD
Duloxetine—Infection—Prednisone—multiple sclerosis	0.000284	0.000501	CcSEcCtD
Duloxetine—Gastrointestinal disorder—Dexamethasone—multiple sclerosis	0.000283	0.0005	CcSEcCtD
Duloxetine—Gastrointestinal disorder—Betamethasone—multiple sclerosis	0.000283	0.0005	CcSEcCtD
Duloxetine—Back pain—Methotrexate—multiple sclerosis	0.000283	0.0005	CcSEcCtD
Duloxetine—Fatigue—Betamethasone—multiple sclerosis	0.000283	0.0005	CcSEcCtD
Duloxetine—Fatigue—Dexamethasone—multiple sclerosis	0.000283	0.0005	CcSEcCtD
Duloxetine—Shock—Prednisone—multiple sclerosis	0.000281	0.000497	CcSEcCtD
Duloxetine—Pain—Betamethasone—multiple sclerosis	0.00028	0.000496	CcSEcCtD
Duloxetine—Pain—Dexamethasone—multiple sclerosis	0.00028	0.000496	CcSEcCtD
Duloxetine—Nervous system disorder—Prednisone—multiple sclerosis	0.00028	0.000495	CcSEcCtD
Duloxetine—Tachycardia—Prednisone—multiple sclerosis	0.000279	0.000493	CcSEcCtD
Duloxetine—Skin disorder—Prednisone—multiple sclerosis	0.000277	0.00049	CcSEcCtD
Duloxetine—Hyperhidrosis—Prednisone—multiple sclerosis	0.000276	0.000488	CcSEcCtD
Duloxetine—Vision blurred—Methotrexate—multiple sclerosis	0.000276	0.000487	CcSEcCtD
Duloxetine—Anorexia—Prednisone—multiple sclerosis	0.000272	0.000481	CcSEcCtD
Duloxetine—Ill-defined disorder—Methotrexate—multiple sclerosis	0.000271	0.00048	CcSEcCtD
Duloxetine—Anaemia—Methotrexate—multiple sclerosis	0.00027	0.000478	CcSEcCtD
Duloxetine—Feeling abnormal—Betamethasone—multiple sclerosis	0.00027	0.000478	CcSEcCtD
Duloxetine—Feeling abnormal—Dexamethasone—multiple sclerosis	0.00027	0.000478	CcSEcCtD
Duloxetine—Gastrointestinal pain—Dexamethasone—multiple sclerosis	0.000268	0.000474	CcSEcCtD
Duloxetine—Gastrointestinal pain—Betamethasone—multiple sclerosis	0.000268	0.000474	CcSEcCtD
Duloxetine—Hypersensitivity—Triamcinolone—multiple sclerosis	0.000266	0.000471	CcSEcCtD
Duloxetine—Hypersensitivity—Methylprednisolone—multiple sclerosis	0.000266	0.00047	CcSEcCtD
Duloxetine—Malaise—Methotrexate—multiple sclerosis	0.000264	0.000466	CcSEcCtD
Duloxetine—Vertigo—Methotrexate—multiple sclerosis	0.000263	0.000464	CcSEcCtD
Duloxetine—Leukopenia—Methotrexate—multiple sclerosis	0.000262	0.000463	CcSEcCtD
Duloxetine—Urticaria—Dexamethasone—multiple sclerosis	0.00026	0.00046	CcSEcCtD
Duloxetine—Urticaria—Betamethasone—multiple sclerosis	0.00026	0.00046	CcSEcCtD
Duloxetine—Musculoskeletal discomfort—Prednisone—multiple sclerosis	0.00026	0.00046	CcSEcCtD
Duloxetine—Dizziness—Prednisolone—multiple sclerosis	0.00026	0.000459	CcSEcCtD
Duloxetine—Asthenia—Triamcinolone—multiple sclerosis	0.000259	0.000458	CcSEcCtD
Duloxetine—Body temperature increased—Betamethasone—multiple sclerosis	0.000259	0.000458	CcSEcCtD
Duloxetine—Abdominal pain—Dexamethasone—multiple sclerosis	0.000259	0.000458	CcSEcCtD
Duloxetine—Abdominal pain—Betamethasone—multiple sclerosis	0.000259	0.000458	CcSEcCtD
Duloxetine—Body temperature increased—Dexamethasone—multiple sclerosis	0.000259	0.000458	CcSEcCtD
Duloxetine—Asthenia—Methylprednisolone—multiple sclerosis	0.000259	0.000457	CcSEcCtD
Duloxetine—Insomnia—Prednisone—multiple sclerosis	0.000258	0.000456	CcSEcCtD
Duloxetine—Paraesthesia—Prednisone—multiple sclerosis	0.000256	0.000453	CcSEcCtD
Duloxetine—Pruritus—Triamcinolone—multiple sclerosis	0.000256	0.000452	CcSEcCtD
Duloxetine—Cough—Methotrexate—multiple sclerosis	0.000255	0.000451	CcSEcCtD
Duloxetine—Pruritus—Methylprednisolone—multiple sclerosis	0.000255	0.000451	CcSEcCtD
Duloxetine—Convulsion—Methotrexate—multiple sclerosis	0.000253	0.000448	CcSEcCtD
Duloxetine—Dyspepsia—Prednisone—multiple sclerosis	0.000251	0.000444	CcSEcCtD
Duloxetine—Chest pain—Methotrexate—multiple sclerosis	0.000249	0.00044	CcSEcCtD
Duloxetine—Arthralgia—Methotrexate—multiple sclerosis	0.000249	0.00044	CcSEcCtD
Duloxetine—Myalgia—Methotrexate—multiple sclerosis	0.000249	0.00044	CcSEcCtD
Duloxetine—Decreased appetite—Prednisone—multiple sclerosis	0.000248	0.000439	CcSEcCtD
Duloxetine—Rash—Prednisolone—multiple sclerosis	0.000248	0.000438	CcSEcCtD
Duloxetine—Dermatitis—Prednisolone—multiple sclerosis	0.000247	0.000437	CcSEcCtD
Duloxetine—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—multiple sclerosis	0.000247	0.000437	CcSEcCtD
Duloxetine—Diarrhoea—Methylprednisolone—multiple sclerosis	0.000247	0.000436	CcSEcCtD
Duloxetine—Fatigue—Prednisone—multiple sclerosis	0.000246	0.000435	CcSEcCtD
Duloxetine—Headache—Prednisolone—multiple sclerosis	0.000246	0.000435	CcSEcCtD
Duloxetine—Discomfort—Methotrexate—multiple sclerosis	0.000246	0.000435	CcSEcCtD
Duloxetine—Constipation—Prednisone—multiple sclerosis	0.000244	0.000432	CcSEcCtD
Duloxetine—Confusional state—Methotrexate—multiple sclerosis	0.000241	0.000425	CcSEcCtD
Duloxetine—Dizziness—Triamcinolone—multiple sclerosis	0.000239	0.000422	CcSEcCtD
Duloxetine—Anaphylactic shock—Methotrexate—multiple sclerosis	0.000239	0.000422	CcSEcCtD
Duloxetine—Dizziness—Methylprednisolone—multiple sclerosis	0.000238	0.000421	CcSEcCtD
Duloxetine—Infection—Methotrexate—multiple sclerosis	0.000237	0.000419	CcSEcCtD
Duloxetine—Feeling abnormal—Prednisone—multiple sclerosis	0.000235	0.000416	CcSEcCtD
Duloxetine—Asthenia—Dexamethasone—multiple sclerosis	0.000235	0.000416	CcSEcCtD
Duloxetine—Asthenia—Betamethasone—multiple sclerosis	0.000235	0.000416	CcSEcCtD
Duloxetine—Nervous system disorder—Methotrexate—multiple sclerosis	0.000234	0.000414	CcSEcCtD
Duloxetine—Thrombocytopenia—Methotrexate—multiple sclerosis	0.000234	0.000413	CcSEcCtD
Duloxetine—Gastrointestinal pain—Prednisone—multiple sclerosis	0.000233	0.000413	CcSEcCtD
Duloxetine—Nausea—Prednisolone—multiple sclerosis	0.000233	0.000413	CcSEcCtD
Duloxetine—Pruritus—Dexamethasone—multiple sclerosis	0.000232	0.00041	CcSEcCtD
Duloxetine—Pruritus—Betamethasone—multiple sclerosis	0.000232	0.00041	CcSEcCtD
Duloxetine—Skin disorder—Methotrexate—multiple sclerosis	0.000232	0.00041	CcSEcCtD
Duloxetine—Hyperhidrosis—Methotrexate—multiple sclerosis	0.000231	0.000408	CcSEcCtD
Duloxetine—Vomiting—Triamcinolone—multiple sclerosis	0.00023	0.000406	CcSEcCtD
Duloxetine—Vomiting—Methylprednisolone—multiple sclerosis	0.000229	0.000405	CcSEcCtD
Duloxetine—Rash—Triamcinolone—multiple sclerosis	0.000228	0.000403	CcSEcCtD
Duloxetine—Dermatitis—Triamcinolone—multiple sclerosis	0.000228	0.000402	CcSEcCtD
Duloxetine—Anorexia—Methotrexate—multiple sclerosis	0.000227	0.000402	CcSEcCtD
Duloxetine—Rash—Methylprednisolone—multiple sclerosis	0.000227	0.000402	CcSEcCtD
Duloxetine—Dermatitis—Methylprednisolone—multiple sclerosis	0.000227	0.000401	CcSEcCtD
Duloxetine—Urticaria—Prednisone—multiple sclerosis	0.000227	0.000401	CcSEcCtD
Duloxetine—Headache—Triamcinolone—multiple sclerosis	0.000226	0.0004	CcSEcCtD
Duloxetine—Headache—Methylprednisolone—multiple sclerosis	0.000226	0.000399	CcSEcCtD
Duloxetine—Body temperature increased—Prednisone—multiple sclerosis	0.000226	0.000399	CcSEcCtD
Duloxetine—Abdominal pain—Prednisone—multiple sclerosis	0.000226	0.000399	CcSEcCtD
Duloxetine—Diarrhoea—Dexamethasone—multiple sclerosis	0.000224	0.000397	CcSEcCtD
Duloxetine—Diarrhoea—Betamethasone—multiple sclerosis	0.000224	0.000397	CcSEcCtD
Duloxetine—Musculoskeletal discomfort—Methotrexate—multiple sclerosis	0.000217	0.000384	CcSEcCtD
Duloxetine—Dizziness—Betamethasone—multiple sclerosis	0.000217	0.000383	CcSEcCtD
Duloxetine—Dizziness—Dexamethasone—multiple sclerosis	0.000217	0.000383	CcSEcCtD
Duloxetine—Insomnia—Methotrexate—multiple sclerosis	0.000216	0.000381	CcSEcCtD
Duloxetine—Nausea—Triamcinolone—multiple sclerosis	0.000215	0.000379	CcSEcCtD
Duloxetine—Paraesthesia—Methotrexate—multiple sclerosis	0.000214	0.000379	CcSEcCtD
Duloxetine—Nausea—Methylprednisolone—multiple sclerosis	0.000214	0.000379	CcSEcCtD
Duloxetine—Somnolence—Methotrexate—multiple sclerosis	0.000212	0.000375	CcSEcCtD
Duloxetine—Hypersensitivity—Prednisone—multiple sclerosis	0.00021	0.000372	CcSEcCtD
Duloxetine—Dyspepsia—Methotrexate—multiple sclerosis	0.00021	0.000371	CcSEcCtD
Duloxetine—Vomiting—Betamethasone—multiple sclerosis	0.000208	0.000368	CcSEcCtD
Duloxetine—Vomiting—Dexamethasone—multiple sclerosis	0.000208	0.000368	CcSEcCtD
Duloxetine—Decreased appetite—Methotrexate—multiple sclerosis	0.000207	0.000367	CcSEcCtD
Duloxetine—Rash—Dexamethasone—multiple sclerosis	0.000207	0.000365	CcSEcCtD
Duloxetine—Rash—Betamethasone—multiple sclerosis	0.000207	0.000365	CcSEcCtD
Duloxetine—Dermatitis—Dexamethasone—multiple sclerosis	0.000207	0.000365	CcSEcCtD
Duloxetine—Dermatitis—Betamethasone—multiple sclerosis	0.000207	0.000365	CcSEcCtD
Duloxetine—Gastrointestinal disorder—Methotrexate—multiple sclerosis	0.000206	0.000364	CcSEcCtD
Duloxetine—Fatigue—Methotrexate—multiple sclerosis	0.000206	0.000364	CcSEcCtD
Duloxetine—Headache—Dexamethasone—multiple sclerosis	0.000205	0.000363	CcSEcCtD
Duloxetine—Headache—Betamethasone—multiple sclerosis	0.000205	0.000363	CcSEcCtD
Duloxetine—Asthenia—Prednisone—multiple sclerosis	0.000205	0.000362	CcSEcCtD
Duloxetine—Pain—Methotrexate—multiple sclerosis	0.000204	0.000361	CcSEcCtD
Duloxetine—Pruritus—Prednisone—multiple sclerosis	0.000202	0.000357	CcSEcCtD
Duloxetine—Feeling abnormal—Methotrexate—multiple sclerosis	0.000197	0.000348	CcSEcCtD
Duloxetine—Diarrhoea—Prednisone—multiple sclerosis	0.000195	0.000345	CcSEcCtD
Duloxetine—Gastrointestinal pain—Methotrexate—multiple sclerosis	0.000195	0.000345	CcSEcCtD
Duloxetine—Nausea—Dexamethasone—multiple sclerosis	0.000195	0.000344	CcSEcCtD
Duloxetine—Nausea—Betamethasone—multiple sclerosis	0.000195	0.000344	CcSEcCtD
Duloxetine—Urticaria—Methotrexate—multiple sclerosis	0.00019	0.000335	CcSEcCtD
Duloxetine—Dizziness—Prednisone—multiple sclerosis	0.000189	0.000334	CcSEcCtD
Duloxetine—Abdominal pain—Methotrexate—multiple sclerosis	0.000189	0.000333	CcSEcCtD
Duloxetine—Body temperature increased—Methotrexate—multiple sclerosis	0.000189	0.000333	CcSEcCtD
Duloxetine—Vomiting—Prednisone—multiple sclerosis	0.000182	0.000321	CcSEcCtD
Duloxetine—Rash—Prednisone—multiple sclerosis	0.00018	0.000318	CcSEcCtD
Duloxetine—Dermatitis—Prednisone—multiple sclerosis	0.00018	0.000318	CcSEcCtD
Duloxetine—Headache—Prednisone—multiple sclerosis	0.000179	0.000316	CcSEcCtD
Duloxetine—Hypersensitivity—Methotrexate—multiple sclerosis	0.000176	0.000311	CcSEcCtD
Duloxetine—Asthenia—Methotrexate—multiple sclerosis	0.000171	0.000303	CcSEcCtD
Duloxetine—Nausea—Prednisone—multiple sclerosis	0.00017	0.0003	CcSEcCtD
Duloxetine—Pruritus—Methotrexate—multiple sclerosis	0.000169	0.000298	CcSEcCtD
Duloxetine—Diarrhoea—Methotrexate—multiple sclerosis	0.000163	0.000289	CcSEcCtD
Duloxetine—Dizziness—Methotrexate—multiple sclerosis	0.000158	0.000279	CcSEcCtD
Duloxetine—Vomiting—Methotrexate—multiple sclerosis	0.000152	0.000268	CcSEcCtD
Duloxetine—Rash—Methotrexate—multiple sclerosis	0.00015	0.000266	CcSEcCtD
Duloxetine—Dermatitis—Methotrexate—multiple sclerosis	0.00015	0.000266	CcSEcCtD
Duloxetine—Headache—Methotrexate—multiple sclerosis	0.000149	0.000264	CcSEcCtD
Duloxetine—Nausea—Methotrexate—multiple sclerosis	0.000142	0.000251	CcSEcCtD
Duloxetine—SLC6A3—NRF2 pathway—TGFB1—multiple sclerosis	0.000141	0.000689	CbGpPWpGaD
Duloxetine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TGFB1—multiple sclerosis	0.000141	0.000689	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—CCL3—multiple sclerosis	0.000141	0.000688	CbGpPWpGaD
Duloxetine—SLC6A3—SLC-mediated transmembrane transport—ALB—multiple sclerosis	0.000141	0.000687	CbGpPWpGaD
Duloxetine—HTR6—GPCR downstream signaling—CCR2—multiple sclerosis	0.00014	0.000686	CbGpPWpGaD
Duloxetine—HTR2A—GPCR downstream signaling—CXCL13—multiple sclerosis	0.000139	0.00068	CbGpPWpGaD
Duloxetine—HTR2A—GPCR downstream signaling—CCR1—multiple sclerosis	0.000139	0.00068	CbGpPWpGaD
Duloxetine—CYP1A2—Aryl Hydrocarbon Receptor—MAPK1—multiple sclerosis	0.000138	0.000676	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—GPR65—multiple sclerosis	0.000138	0.000676	CbGpPWpGaD
Duloxetine—HTR2A—SIDS Susceptibility Pathways—IL1B—multiple sclerosis	0.000136	0.000665	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—PTGER4—multiple sclerosis	0.000136	0.000663	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—SPP1—multiple sclerosis	0.000135	0.00066	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—RGS1—multiple sclerosis	0.000135	0.000658	CbGpPWpGaD
Duloxetine—HTR2A—Class A/1 (Rhodopsin-like receptors)—CCR5—multiple sclerosis	0.000135	0.000657	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—LINGO1—multiple sclerosis	0.000134	0.000653	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—TAGAP—multiple sclerosis	0.000134	0.000652	CbGpPWpGaD
Duloxetine—SLC6A4—SIDS Susceptibility Pathways—IL6—multiple sclerosis	0.000132	0.000647	CbGpPWpGaD
Duloxetine—HTR2A—GPCR ligand binding—CXCL10—multiple sclerosis	0.000132	0.000645	CbGpPWpGaD
Duloxetine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—multiple sclerosis	0.000132	0.000643	CbGpPWpGaD
Duloxetine—CYP1A2—Aryl Hydrocarbon Receptor—TNF—multiple sclerosis	0.000132	0.000643	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—CCR5—multiple sclerosis	0.000132	0.000642	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—CXCR3—multiple sclerosis	0.000131	0.00064	CbGpPWpGaD
Duloxetine—HTR2C—GPCR ligand binding—CCL5—multiple sclerosis	0.000131	0.000639	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—IL2RA—multiple sclerosis	0.00013	0.000633	CbGpPWpGaD
Duloxetine—HTR6—GPCR downstream signaling—CNR1—multiple sclerosis	0.00013	0.000633	CbGpPWpGaD
Duloxetine—NPY1R—Signaling by GPCR—IL2—multiple sclerosis	0.000129	0.000628	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—GPR65—multiple sclerosis	0.000128	0.000624	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—CCR2—multiple sclerosis	0.000128	0.000623	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—CCR1—multiple sclerosis	0.000127	0.000618	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—CXCL13—multiple sclerosis	0.000127	0.000618	CbGpPWpGaD
Duloxetine—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—TYK2—multiple sclerosis	0.000126	0.000616	CbGpPWpGaD
Duloxetine—HTR6—GPCR ligand binding—POMC—multiple sclerosis	0.000125	0.000611	CbGpPWpGaD
Duloxetine—HTR6—GPCR ligand binding—CCL2—multiple sclerosis	0.000123	0.000598	CbGpPWpGaD
Duloxetine—HTR2C—Class A/1 (Rhodopsin-like receptors)—POMC—multiple sclerosis	0.000121	0.000591	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—APOE—multiple sclerosis	0.00012	0.000585	CbGpPWpGaD
Duloxetine—HTR2C—Class A/1 (Rhodopsin-like receptors)—CCL2—multiple sclerosis	0.000118	0.000578	CbGpPWpGaD
Duloxetine—HTR2C—GPCR ligand binding—CCR5—multiple sclerosis	0.000118	0.000576	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—CNR1—multiple sclerosis	0.000118	0.000575	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—CCR1—multiple sclerosis	0.000117	0.000571	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—CXCL13—multiple sclerosis	0.000117	0.000571	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—S1PR1—multiple sclerosis	0.000117	0.00057	CbGpPWpGaD
Duloxetine—HTR6—GPCR downstream signaling—CXCL10—multiple sclerosis	0.000117	0.00057	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—TAGAP—multiple sclerosis	0.000116	0.000566	CbGpPWpGaD
Duloxetine—HTR2A—GPCR ligand binding—CCL5—multiple sclerosis	0.000114	0.000555	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—GPC5—multiple sclerosis	0.000114	0.000555	CbGpPWpGaD
Duloxetine—HTR2C—GPCR downstream signaling—PTGER4—multiple sclerosis	0.00011	0.000537	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—SRM—multiple sclerosis	0.000109	0.00053	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—CD80—multiple sclerosis	0.000108	0.000528	CbGpPWpGaD
Duloxetine—SLC6A4—Circadian rythm related genes—IL6—multiple sclerosis	0.000108	0.000528	CbGpPWpGaD
Duloxetine—SLC6A3—Transmission across Chemical Synapses—MAPK1—multiple sclerosis	0.000108	0.000525	CbGpPWpGaD
Duloxetine—HTR2C—GPCR downstream signaling—CXCR3—multiple sclerosis	0.000106	0.000519	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—CXCL10—multiple sclerosis	0.000106	0.000517	CbGpPWpGaD
Duloxetine—HTR2A—Class A/1 (Rhodopsin-like receptors)—POMC—multiple sclerosis	0.000105	0.000513	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—CCL3—multiple sclerosis	0.000104	0.000507	CbGpPWpGaD
Duloxetine—HTR2C—GPCR downstream signaling—CCR2—multiple sclerosis	0.000103	0.000505	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—POMC—multiple sclerosis	0.000103	0.000502	CbGpPWpGaD
Duloxetine—HTR2A—Class A/1 (Rhodopsin-like receptors)—CCL2—multiple sclerosis	0.000103	0.000502	CbGpPWpGaD
Duloxetine—HTR2A—GPCR ligand binding—CCR5—multiple sclerosis	0.000102	0.0005	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—S1PR1—multiple sclerosis	0.000101	0.000495	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—CCL2—multiple sclerosis	0.000101	0.000491	CbGpPWpGaD
Duloxetine—CYP2D6—Biological oxidations—POMC—multiple sclerosis	0.000101	0.000491	CbGpPWpGaD
Duloxetine—HTR6—GPCR downstream signaling—CCL5—multiple sclerosis	0.0001	0.00049	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—PTGER4—multiple sclerosis	0.0001	0.000488	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—RGS1—multiple sclerosis	9.93e-05	0.000485	CbGpPWpGaD
Duloxetine—HTR2A—SIDS Susceptibility Pathways—TNF—multiple sclerosis	9.88e-05	0.000482	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—GPC5—multiple sclerosis	9.87e-05	0.000482	CbGpPWpGaD
Duloxetine—NPY1R—Signaling by GPCR—MAPK1—multiple sclerosis	9.85e-05	0.000481	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—CXCR3—multiple sclerosis	9.66e-05	0.000471	CbGpPWpGaD
Duloxetine—HTR2A—GPCR downstream signaling—PTGER4—multiple sclerosis	9.56e-05	0.000467	CbGpPWpGaD
Duloxetine—HTR2C—GPCR downstream signaling—CNR1—multiple sclerosis	9.55e-05	0.000466	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—GPR65—multiple sclerosis	9.42e-05	0.00046	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—CCR2—multiple sclerosis	9.4e-05	0.000458	CbGpPWpGaD
Duloxetine—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—MAPK1—multiple sclerosis	9.25e-05	0.000451	CbGpPWpGaD
Duloxetine—HTR2A—GPCR downstream signaling—CXCR3—multiple sclerosis	9.24e-05	0.000451	CbGpPWpGaD
Duloxetine—HTR2C—GPCR ligand binding—POMC—multiple sclerosis	9.22e-05	0.00045	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—SRM—multiple sclerosis	9.2e-05	0.000449	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—TYK2—multiple sclerosis	9.14e-05	0.000446	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—CCL5—multiple sclerosis	9.13e-05	0.000445	CbGpPWpGaD
Duloxetine—HTR6—GPCR downstream signaling—CCR5—multiple sclerosis	9.05e-05	0.000442	CbGpPWpGaD
Duloxetine—HTR2C—GPCR ligand binding—CCL2—multiple sclerosis	9.02e-05	0.00044	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—CCL3—multiple sclerosis	9.02e-05	0.00044	CbGpPWpGaD
Duloxetine—HTR2A—GPCR downstream signaling—CCR2—multiple sclerosis	8.98e-05	0.000438	CbGpPWpGaD
Duloxetine—HTR6—GPCR downstream signaling—IL2RA—multiple sclerosis	8.92e-05	0.000435	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—PTGER4—multiple sclerosis	8.68e-05	0.000424	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—CNR1—multiple sclerosis	8.67e-05	0.000423	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—RGS1—multiple sclerosis	8.63e-05	0.000421	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—CXCL13—multiple sclerosis	8.61e-05	0.00042	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—CCR1—multiple sclerosis	8.61e-05	0.00042	CbGpPWpGaD
Duloxetine—HTR2C—GPCR downstream signaling—CXCL10—multiple sclerosis	8.6e-05	0.00042	CbGpPWpGaD
Duloxetine—CYP1A2—Biological oxidations—POMC—multiple sclerosis	8.52e-05	0.000416	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—CXCR3—multiple sclerosis	8.39e-05	0.000409	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—CCL3—multiple sclerosis	8.33e-05	0.000407	CbGpPWpGaD
Duloxetine—HTR2A—GPCR downstream signaling—CNR1—multiple sclerosis	8.29e-05	0.000405	CbGpPWpGaD
Duloxetine—SLC6A3—Neuronal System—MAPK1—multiple sclerosis	8.25e-05	0.000403	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—CCR5—multiple sclerosis	8.22e-05	0.000401	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—GPR65—multiple sclerosis	8.18e-05	0.000399	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—CCR2—multiple sclerosis	8.16e-05	0.000398	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—IL2RA—multiple sclerosis	8.1e-05	0.000395	CbGpPWpGaD
Duloxetine—SLC6A2—Transmembrane transport of small molecules—ALB—multiple sclerosis	8.07e-05	0.000394	CbGpPWpGaD
Duloxetine—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—MAPK1—multiple sclerosis	8.03e-05	0.000392	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—PTGER4—multiple sclerosis	8.02e-05	0.000391	CbGpPWpGaD
Duloxetine—HTR2A—GPCR ligand binding—POMC—multiple sclerosis	8.01e-05	0.000391	CbGpPWpGaD
Duloxetine—HTR2A—SIDS Susceptibility Pathways—IL6—multiple sclerosis	7.98e-05	0.000389	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—PGR—multiple sclerosis	7.9e-05	0.000386	CbGpPWpGaD
Duloxetine—HTR2A—GPCR ligand binding—CCL2—multiple sclerosis	7.83e-05	0.000382	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—CXCL10—multiple sclerosis	7.81e-05	0.000381	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—CXCR3—multiple sclerosis	7.75e-05	0.000378	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—CD28—multiple sclerosis	7.67e-05	0.000375	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—CYP27B1—multiple sclerosis	7.65e-05	0.000373	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—CYP24A1—multiple sclerosis	7.65e-05	0.000373	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—IL2—multiple sclerosis	7.61e-05	0.000371	CbGpPWpGaD
Duloxetine—NPY1R—Signaling by GPCR—IL6—multiple sclerosis	7.57e-05	0.000369	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—CCR2—multiple sclerosis	7.54e-05	0.000368	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—CNR1—multiple sclerosis	7.53e-05	0.000367	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—CXCL13—multiple sclerosis	7.48e-05	0.000365	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—CCR1—multiple sclerosis	7.48e-05	0.000365	CbGpPWpGaD
Duloxetine—HTR2A—GPCR downstream signaling—CXCL10—multiple sclerosis	7.47e-05	0.000364	CbGpPWpGaD
Duloxetine—HTR2C—GPCR downstream signaling—CCL5—multiple sclerosis	7.4e-05	0.000361	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—MMP9—multiple sclerosis	7.2e-05	0.000351	CbGpPWpGaD
Duloxetine—SLC6A3—Transmembrane transport of small molecules—ALB—multiple sclerosis	7.15e-05	0.000349	CbGpPWpGaD
Duloxetine—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—multiple sclerosis	7.11e-05	0.000347	CbGpPWpGaD
Duloxetine—HTR6—GPCR downstream signaling—POMC—multiple sclerosis	7.08e-05	0.000345	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—GPC5—multiple sclerosis	7e-05	0.000341	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—CNR1—multiple sclerosis	6.96e-05	0.000339	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—CXCL10—multiple sclerosis	6.78e-05	0.000331	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—CCL5—multiple sclerosis	6.72e-05	0.000328	CbGpPWpGaD
Duloxetine—HTR2C—GPCR downstream signaling—CCR5—multiple sclerosis	6.67e-05	0.000325	CbGpPWpGaD
Duloxetine—HTR2C—GPCR downstream signaling—IL2RA—multiple sclerosis	6.57e-05	0.000321	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—CYP27B1—multiple sclerosis	6.48e-05	0.000316	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—CYP24A1—multiple sclerosis	6.48e-05	0.000316	CbGpPWpGaD
Duloxetine—HTR2A—GPCR downstream signaling—CCL5—multiple sclerosis	6.43e-05	0.000314	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—POMC—multiple sclerosis	6.43e-05	0.000314	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—STAT3—multiple sclerosis	6.4e-05	0.000312	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—BCHE—multiple sclerosis	6.33e-05	0.000309	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—CCL2—multiple sclerosis	6.29e-05	0.000307	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—CXCL10—multiple sclerosis	6.26e-05	0.000306	CbGpPWpGaD
Duloxetine—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—multiple sclerosis	6.17e-05	0.000301	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—CCL3—multiple sclerosis	6.14e-05	0.000299	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—CCR5—multiple sclerosis	6.05e-05	0.000295	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—IL2RA—multiple sclerosis	5.97e-05	0.000291	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—MYC—multiple sclerosis	5.95e-05	0.00029	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—TGFB1—multiple sclerosis	5.93e-05	0.00029	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—GPC5—multiple sclerosis	5.93e-05	0.000289	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—PTGER4—multiple sclerosis	5.91e-05	0.000288	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—CCL5—multiple sclerosis	5.84e-05	0.000285	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—MAPK1—multiple sclerosis	5.82e-05	0.000284	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—PGR—multiple sclerosis	5.82e-05	0.000284	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—RRM1—multiple sclerosis	5.8e-05	0.000283	CbGpPWpGaD
Duloxetine—HTR2A—GPCR downstream signaling—CCR5—multiple sclerosis	5.79e-05	0.000283	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—TYK2—multiple sclerosis	5.71e-05	0.000279	CbGpPWpGaD
Duloxetine—HTR2A—GPCR downstream signaling—IL2RA—multiple sclerosis	5.71e-05	0.000278	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—CXCR3—multiple sclerosis	5.71e-05	0.000278	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—CD28—multiple sclerosis	5.65e-05	0.000276	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—CCR2—multiple sclerosis	5.55e-05	0.000271	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—CD86—multiple sclerosis	5.48e-05	0.000267	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—CCL5—multiple sclerosis	5.39e-05	0.000263	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—CCL3—multiple sclerosis	5.33e-05	0.00026	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—CCR5—multiple sclerosis	5.26e-05	0.000257	CbGpPWpGaD
Duloxetine—HTR6—GPCR downstream signaling—IL2—multiple sclerosis	5.23e-05	0.000255	CbGpPWpGaD
Duloxetine—HTR2C—GPCR downstream signaling—POMC—multiple sclerosis	5.21e-05	0.000254	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—IL2RA—multiple sclerosis	5.18e-05	0.000253	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—PTGER4—multiple sclerosis	5.13e-05	0.00025	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—CNR1—multiple sclerosis	5.12e-05	0.00025	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—PGR—multiple sclerosis	5.05e-05	0.000247	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—SPP1—multiple sclerosis	4.99e-05	0.000244	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—CXCR3—multiple sclerosis	4.95e-05	0.000242	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—RRM1—multiple sclerosis	4.91e-05	0.00024	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—CD28—multiple sclerosis	4.91e-05	0.00024	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—CCR5—multiple sclerosis	4.86e-05	0.000237	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—CCR2—multiple sclerosis	4.82e-05	0.000235	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—IL2RA—multiple sclerosis	4.79e-05	0.000234	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—IL2—multiple sclerosis	4.75e-05	0.000232	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—POMC—multiple sclerosis	4.73e-05	0.000231	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—CCL2—multiple sclerosis	4.63e-05	0.000226	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—CXCL10—multiple sclerosis	4.61e-05	0.000225	CbGpPWpGaD
Duloxetine—HTR2A—GPCR downstream signaling—POMC—multiple sclerosis	4.52e-05	0.000221	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—IL6—multiple sclerosis	4.47e-05	0.000218	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—CNR1—multiple sclerosis	4.45e-05	0.000217	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—APOE—multiple sclerosis	4.42e-05	0.000216	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—TYK2—multiple sclerosis	4.2e-05	0.000205	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—POMC—multiple sclerosis	4.11e-05	0.000201	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—CD86—multiple sclerosis	4.03e-05	0.000197	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—CCL2—multiple sclerosis	4.02e-05	0.000196	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—CXCL10—multiple sclerosis	4e-05	0.000195	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—CD80—multiple sclerosis	3.99e-05	0.000195	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—CCL5—multiple sclerosis	3.97e-05	0.000194	CbGpPWpGaD
Duloxetine—HTR2C—GPCR downstream signaling—IL2—multiple sclerosis	3.85e-05	0.000188	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—APOE—multiple sclerosis	3.81e-05	0.000186	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—POMC—multiple sclerosis	3.8e-05	0.000185	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—CCL2—multiple sclerosis	3.71e-05	0.000181	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—SPP1—multiple sclerosis	3.68e-05	0.000179	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—TYK2—multiple sclerosis	3.65e-05	0.000178	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—MAPK1—multiple sclerosis	3.63e-05	0.000177	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—CCR5—multiple sclerosis	3.58e-05	0.000175	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—IL2RA—multiple sclerosis	3.52e-05	0.000172	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—CD86—multiple sclerosis	3.5e-05	0.000171	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—IL2—multiple sclerosis	3.5e-05	0.000171	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—CCL5—multiple sclerosis	3.45e-05	0.000168	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—TYK2—multiple sclerosis	3.37e-05	0.000165	CbGpPWpGaD
Duloxetine—HTR2A—GPCR downstream signaling—IL2—multiple sclerosis	3.34e-05	0.000163	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—BCHE—multiple sclerosis	3.33e-05	0.000163	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—POMC—multiple sclerosis	3.27e-05	0.00016	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—APOE—multiple sclerosis	3.25e-05	0.000159	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—SPP1—multiple sclerosis	3.19e-05	0.000156	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—CCR5—multiple sclerosis	3.11e-05	0.000152	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—IL2RA—multiple sclerosis	3.06e-05	0.000149	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—IL2—multiple sclerosis	3.04e-05	0.000148	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—ALB—multiple sclerosis	2.98e-05	0.000146	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—CD80—multiple sclerosis	2.94e-05	0.000144	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—APOE—multiple sclerosis	2.83e-05	0.000138	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—BCHE—multiple sclerosis	2.82e-05	0.000138	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—IL2—multiple sclerosis	2.81e-05	0.000137	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—POMC—multiple sclerosis	2.8e-05	0.000136	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—IL6—multiple sclerosis	2.79e-05	0.000136	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—CCL2—multiple sclerosis	2.73e-05	0.000133	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—MAPK1—multiple sclerosis	2.68e-05	0.000131	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—MMP9—multiple sclerosis	2.66e-05	0.00013	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—CD80—multiple sclerosis	2.55e-05	0.000125	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—TYK2—multiple sclerosis	2.48e-05	0.000121	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—POMC—multiple sclerosis	2.43e-05	0.000118	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—CCL2—multiple sclerosis	2.37e-05	0.000116	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—STAT3—multiple sclerosis	2.36e-05	0.000115	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—MAPK1—multiple sclerosis	2.32e-05	0.000113	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—MYC—multiple sclerosis	2.19e-05	0.000107	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—TGFB1—multiple sclerosis	2.19e-05	0.000107	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—TYK2—multiple sclerosis	2.16e-05	0.000105	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—MAPK1—multiple sclerosis	2.15e-05	0.000105	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—IL2—multiple sclerosis	2.07e-05	0.000101	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—IL6—multiple sclerosis	2.06e-05	0.0001	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—APOE—multiple sclerosis	2e-05	9.78e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—MMP9—multiple sclerosis	1.96e-05	9.54e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—IL2—multiple sclerosis	1.79e-05	8.76e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—IL6—multiple sclerosis	1.79e-05	8.71e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—STAT3—multiple sclerosis	1.74e-05	8.49e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—POMC—multiple sclerosis	1.72e-05	8.4e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—MMP9—multiple sclerosis	1.7e-05	8.29e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—APOE—multiple sclerosis	1.7e-05	8.28e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—IL6—multiple sclerosis	1.65e-05	8.05e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—MYC—multiple sclerosis	1.62e-05	7.89e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—TGFB1—multiple sclerosis	1.61e-05	7.87e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—MAPK1—multiple sclerosis	1.58e-05	7.71e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—ALB—multiple sclerosis	1.57e-05	7.66e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—STAT3—multiple sclerosis	1.51e-05	7.37e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—POMC—multiple sclerosis	1.46e-05	7.11e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—MYC—multiple sclerosis	1.4e-05	6.85e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—TGFB1—multiple sclerosis	1.4e-05	6.83e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—MAPK1—multiple sclerosis	1.37e-05	6.7e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—ALB—multiple sclerosis	1.33e-05	6.49e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—IL6—multiple sclerosis	1.21e-05	5.93e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—IL6—multiple sclerosis	1.05e-05	5.15e-05	CbGpPWpGaD
